Moleculin Announces Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate Apr 14, 2020
Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100% Apr 8, 2020
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus Mar 17, 2020
Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date Feb 20, 2020
